Stockreport

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in pos [Read more]